AKUMS DRUGS & PHARMACEUTICALS
|
|
| BOM : 544222     NSE : AKUMS     | |
| LT :  
    Long Term Analysis
Fundamentals : Average
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
| ST :  
    Short Term Analysis
Quarterly Earnings Trend : Upward
Price Momentum : Upward Pledged Shares : None or < 25% |
Aug 20,2026 |
|
Price(EOD): ₹ 753.20
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
| MCap: ₹ 11,855.37 Cr | |
| Industry Peers & Returns | 1W | 1M | 1Y |
| AKUMS DRUGS & PHARMACEUTICALS | 3.6% | 8.2% | 54.2% |
| SUN PHARMACEUTICAL INDUSTRIES | -1.2% | -2.2% | 15.8% |
| DIVIS LABORATORIES | 1% | 16.3% | 39.7% |
| TORRENT PHARMACEUTICALS | 3.2% | -0.8% | 38.6% |
| CIPLA | -0.9% | 1.6% | -9.3% |
| DR REDDYS LABORATORIES | -1.7% | -0.1% | -6.5% |
| MANKIND PHARMA | -1.5% | -6.3% | -3% |
| LUPIN | -1.4% | -8.4% | 11.6% |
| ZYDUS LIFESCIENCES | -2.7% | -1.9% | 11.7% |
FUNDAMENTAL ANALYSIS OF AKUMS DRUGS & PHARMACEUTICALS
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF AKUMS DRUGS & PHARMACEUTICALS
 | Ratio | Consolidated | |
|---|---|---|
|
P/E P/B P/S |
40.5
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 292.69 Cr
[Latest Qtr - Jun2026 - Consolidated Results ] 3.58
P/B Calculated based on Book Value of Rs 3,313.35 Cr
[Latest Year - Mar2026 - Consolidated Results ] 2.63
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 4,501.61 Cr
[Latest Qtr - Jun2026 - Consolidated Results ] |
|
| Financial Ratios → | ||
| Model | Discount(-)/ Premium(+) |
|---|---|
|
EV/EBIDTA EV/Sales Price/Sales |
829% 1151% 42% |
SHARE PRICE MOMENTUM OF AKUMS DRUGS & PHARMACEUTICALS
AKUMS DRUGS & PHARMACEUTICALS vs SENSEX
DEBT OF AKUMS DRUGS & PHARMACEUTICALS
| Year | Debt/Equity ratio | |
|---|---|---|
| Standalone | Consolidated | |
|
2026 2025 2024 Avg_3yrs |
0.01 0 1.57 0.53 |
0.02 0 0.69 0.24 |
|
[Last Annual Data : Mar2026]
|
||
| Financial Ratios → | ||
PLEDGED PROMOTER SHARES OF AKUMS DRUGS & PHARMACEUTICALS
| Pledged Promoter Shares |
0 % | |
|---|---|---|
| As on : Jun2026 | ||
If less than 25% | Good |
|
| If between 25% and 50% | Neutral | |
| If greater than 50% | Bad | |
| Shareholding Pattern → | ||
QTRLY RESULTS OF AKUMS DRUGS & PHARMACEUTICALS
| Consolidated | Q-o-Q | Y-o-Y |
|---|---|---|
|
Revenue Op Profit Profit Before Tax Profit After Tax |
0.76% 15.13% 14.87% 24.14% |
13.93% 35.44% 45.58% 56.11% |
| QtrlyTrend |
8 | |
| Latest Qtr: Jun2026 | ||
| Quarterly Result Analysis → | ||
AKUMS DRUGS & PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE 1000 | -0.5% | 1% | 4.5% |
| BSE HEALTHCARE | -0.6% | 0.5% | 15.7% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MICROCAP 250 | 0.5% | 3.9% | 13.6% |
| NIFTY SMALLCAP 500 | 0% | 2.1% | NA |
| NIFTY MIDSMALLCAP400 50:50 | -0.4% | 1.1% | NA |
| NIFTY 500 EQUAL WEIGHT | -0.4% | 0.9% | 8.7% |
| NIFTY500 LARGEMIDSMALL EQUAL-CAP WEIGHTED INDEX | -0.5% | 0.9% | 7.8% |
You may also like the below Video Courses
FAQ about AKUMS DRUGS & PHARMACEUTICALS
Is AKUMS DRUGS & PHARMACEUTICALS good for long term investment?
As on Aug 20,2026, the Fundamentals of AKUMS DRUGS & PHARMACEUTICALS look Average and hence you may wait for the results to improve to invest for long term ! See Financial Performance of AKUMS DRUGS & PHARMACEUTICALS . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is AKUMS DRUGS & PHARMACEUTICALS UnderValued or OverValued?
As on Aug 20,2026, AKUMS DRUGS & PHARMACEUTICALS is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of AKUMS DRUGS & PHARMACEUTICALS ?
As on Aug 20,2026, the Intrinsic Value of AKUMS DRUGS & PHARMACEUTICALS is Rs. 81.04 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 81.04
Fair Value [Median EV / Sales Model] : Rs. 60.20
Fair Value [Median Price / Sales Model] : Rs. 532.16
Estimated Median Fair Value of AKUMS DRUGS & PHARMACEUTICALS : Rs. 81.04
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.